Larimar Therapeutics (LRMR) to Release Quarterly Earnings on Thursday

Larimar Therapeutics (NASDAQ:LRMR) is anticipated to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

Larimar Therapeutics Stock Performance

NASDAQ:LRMR opened at $2.65 on Wednesday. The firm has a market cap of $169.09 million, a PE ratio of -2.30 and a beta of 0.99. The business has a 50 day moving average price of $3.40 and a 200-day moving average price of $5.58. Larimar Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $11.20.

Analyst Ratings Changes

LRMR has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Larimar Therapeutics in a report on Friday, January 24th. William Blair restated an “outperform” rating on shares of Larimar Therapeutics in a report on Tuesday, November 19th. Finally, Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They set a “buy” rating and a $18.00 target price for the company. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $20.13.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.